BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 06, 2010
 |  BC Week In Review  |  Company News  |  Deals

Orexigen, Takeda deal

Orexigen granted Takeda exclusive rights to commercialize obesity candidate Contrave in the U.S., Canada and Mexico. Orexigen, which retains a right to co-promote Contrave in the U.S., will receive $50 million up front and is eligible for more...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >